E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis
View abstract on PubMed
Summary
This summary is machine-generated.A newly identified protein, UCP, destabilizes the von Hippel-Lindau tumor suppressor (pVHL), stabilizing HIF-1alpha. This pathway promotes cancer growth and metastasis, suggesting UCP as a potential therapeutic target for human cancers.
Area Of Science
- Oncology
- Molecular Biology
- Biochemistry
Background
- The von Hippel-Lindau tumor suppressor (pVHL) is crucial in regulating hypoxia-inducible factor-1alpha (HIF-1alpha), a key player in tumor progression and angiogenesis.
- The precise mechanisms underlying pVHL destabilization and subsequent HIF-1alpha stabilization in cancer remain incompletely understood.
Purpose Of The Study
- To elucidate the molecular mechanisms by which pVHL is destabilized.
- To investigate the role of E2-EPF ubiquitin carrier protein (UCP) in the pVHL-HIF pathway and its implications in human cancers.
Main Methods
- Co-immunoprecipitation assays to demonstrate the association between UCP and pVHL.
- Ubiquitination assays to confirm UCP's role in targeting pVHL for proteasomal degradation.
- Analysis of UCP and pVHL expression in human tumor samples and cell lines.
- In vitro and in vivo experiments assessing the functional impact of UCP expression on tumor cell behavior.
Main Results
- E2-EPF ubiquitin carrier protein (UCP) directly associates with and targets pVHL for ubiquitin-mediated proteolysis.
- UCP-mediated destabilization of pVHL leads to the stabilization of HIF-1alpha.
- UCP expression is detected in various human primary tumors and metastatic cancer cells, often inversely correlating with pVHL levels.
- Forced UCP expression enhances tumor cell proliferation, invasion, and metastasis by modulating the pVHL-HIF pathway.
Conclusions
- UCP plays a significant role in destabilizing pVHL, consequently stabilizing HIF-1alpha and promoting cancer progression.
- UCP represents a novel molecular target for therapeutic intervention in human cancers, particularly those driven by the pVHL-HIF pathway.